Rahul Banerjee: What Changes Once SQ Isatuximab Approved?
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared a post by Integrity CE, LLC on X:
”Open question: what changes once SQ isatuximab approved?
Comparing CD38-VRd between GMMG-HD7 (Marc S. Raab, Elias K. Mai et al) and PERSEUS, one difference is no post-ASCT consolidation in HD7 – unclear if will be different in real life.
Anything else?”
Quoting Integrity CE, LLC ‘s post:
”1. Primary treatment approach in NDMM with Saad Z. Usmani, Rahul Banerjee, and Surbhi Sidana! Supported by educational grants from Janssen and Sanofi.
What is your specialty/degree?
- Hem Onc MD/DO
- Med Onc MD/DO
- APP
- Other
2. What have we learned from key studies of anti-CD38 mAb quad regimens for patients with transplant eligible NDMM?
- Dara-VRd, Ph3 PERSEUS
- Isa-VRd, Ph3 BENEFIT
- Isa-KRd, Ph3 IsKia
- Dara-KRd, Ph2 MASTER
3. Which induction treatment would you select for a healthy 62-year-old woman with NDMM with standard-risk cytogenetics who is transplant eligible?
- Dara-based quad
- Isa-based quad
- Triplet
- Other
4. What quad regimens for patients with transplant eligible NDMM are included in current guidelines? What have we learned from new data?
Saad Z. Usmani wil tell you all about it in the video bellow!
5. Which induction treatment would you select for a healthy 62-year-old woman with NDMM with standard-risk cytogenetics who is transplant eligible MMBrief MSMM?
- Dara-based quad
- Isa-based quad
- Triplet
- Other
6. We hope you enjoyed this MMBrief!
Complete the posttest and evaluation here and claim your CME!
See you for our next MMBrief with Saad Z. Usmani and Rahul Banerjee!”
Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023